Pfizer receives a tactical upgrade to Hold following its acquisition of Metsera, re-entering the obesity/GLP-1 market with promising clinical assets. The Metsera deal offers PFE strategic optionality ...

Pfizer is one of the world's largest and oldest drug companies. Thanks to its Covid vaccine, shares rose dramatically during the pandemic. Now that the stock has sharply corrected, long-term investors ...

Pfizer’s revenue soared to record heights a few years ago thanks to its coronavirus products, but growth has since slowed. The company is counting on new products, and a focus on oncology, to drive ...

Pfizer's third-quarter sales fell 6% year over year to $16.65 billion, beating the consensus of $16.59 billion. The revenue reflected an operational decline of 7%. The operational decrease was ...

Pfizer Ventures announced its investment in Vibrant Therapeutics, a clinical-stage biotechnology company. The $61 million financing round included new investor Apricot Capital, with participation from ...

Pfizer has agreed to acquire Metsera, a clinical-stage biopharmaceutical company. The transaction, announced Sept. 22, is valued at $47.50 per Metsera share in cash upon closing, for an initial ...